Showing results (1861-1870 of 2,138) with videos related to

Sort By:
Pageof 214
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Science (New York, N.Y.)|January 31, 1997
Identification of a gene that causes primary open angle glaucomaE M Stone, J H Fingert, W L Alward, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
Plos One|March 29, 2013
A genome-wide association study for primary open angle glaucoma and macular degeneration reveals novel LociTodd E Scheetz, John H Fingert, Kai Wang, et al.
Cancer Discovery|December 18, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxJoan Montero, Jason Stephansky, Tianyu Cai, et al.
Blood|November 11, 2006
End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum, Daniel Rosenblum, Robert J Arceci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Blood|October 7, 2024
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemiaMarlise R Luskin, Mark A Murakami, Julia Keating, et al.
Leukemia|March 23, 2018
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studiesAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Pageof 214